UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): July 122, 2022

Alfi, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-40294	30-1107078
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

429 Lenox Avenue
Miami Beach, Florida	33139
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code:

(305) 395-4520

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	ALF	Nasdaq Capital Market
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $4.57	ALFIW	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 122, 2022, ~~Allen Capsuto, a member of~~ the Board of Directors (the “Board”) of Alfi, Inc. (the “Company”) ~~and~~appointed James Lee, the current Chairman of the ~~Audit~~Board, ~~Committee~~to ofserve as the ~~Board~~Company’s ~~(the~~Interim ~~“Audit~~Chief ~~Committee”),~~Executive ~~notified~~Officer ~~the~~effective ~~Company~~as ~~that~~of hesuch isdate. ~~resigning~~As ~~his~~Interim ~~position~~Chief Executive asOfficer, aMr. ~~director~~Lee ofwill serve as the Company’s ~~and~~principal asexecutive ~~Audit~~officer. ~~Committee~~The ~~Chair~~Board, ~~effective~~upon ~~July~~recommendation 14of its Compensation Committee, has ~~2022.~~determined that Mr. ~~Capsuto’s~~Lee ~~resignation~~will is not ~~because~~receive ~~of a~~any ~~disagreement~~compensation ~~with~~from the Company onfor ~~any~~his ~~matter~~service ~~relating~~as tothe Company’s Interim Chief Executive Officer. Mr. Lee replaces Peter Bordes as the Company’s ~~operations~~Interim Chief Executive Officer, ~~policies~~effective orJuly ~~practices~~22, 2022. Mr. Bordes continues to serve as a director of the Company.

OnMr. ~~July 7~~Lee, ~~2022~~age 63, has served as Chairman of the Board since October 22, ~~upon~~2021 ~~recommendation~~and a director of the ~~Nominating~~Company since July 2018. Mr. Lee has been the founder, President and ~~Corporate~~Chief ~~Governance~~Executive ~~Committee~~Officer of Lee Aerospace, Inc., a transparency manufacturer for the ~~Board~~aerospace industry, ~~appointed~~since 1987. ~~Jeremy~~Additional Dbiographical and other information concerning Mr. ~~Daniel to~~Lee, ~~serve~~including asinformation areportable ~~director~~under Item 404(a) of Regulation S-K, can be found in: (i) the Company’s toAnnual ~~fill~~Report on Form 10-K, filed with the ~~vacancy~~Securities onand Exchange Commission (the ~~Board~~“SEC”) on ~~created~~May by16, ~~Mr.~~2022, ~~Capsuto~~under (a) Part II, Item 5 “Market for Registrant’s ~~resignation~~Common Equity, ~~effective~~Related ~~July~~Stockholder ~~14, 2022~~Matters and ~~immediately~~Issuer Purchases ~~upon~~of ~~the~~Equity ~~effectiveness~~Securities – Recent Sales of ~~such~~Unregistered ~~resignation~~Securities” and “ – Use of Proceeds From Registered Securities”, (~~the~~b) Part III, Item 10 “~~Effective~~Directors, ~~Time~~Executive Officers and Corporate Governance – Information About Executive Officers and Directors – James Lee”, and (c). ~~The~~Part ~~Board~~III, ~~also~~Item ~~appointed~~13 ~~Mr.~~“Certain ~~Daniel~~Relationships and Related Transactions, and asDirector aIndependence ~~member~~– ofRelated Party Transactions”; (ii) the ~~Audit~~Company’s ~~Committee~~Current ~~and~~Report ason ~~Audit~~Form ~~Committee~~8-K, ~~Chair~~filed with the SEC on April 18, in2022; ~~each~~and ~~case~~(iii) ~~effective~~the asCompany’s ofCurrent Report on Form 8-K, filed with the ~~Effective~~SEC ~~Time~~on July 1, 2022. All such information is incorporated into this Item 5.02 by reference.

Mr. Daniel, age 46, has served since 2019 as the Chief Financial Officer of H-CYTE, Inc. (“H-CYTE”), a public reporting hybrid biopharmaceutical company dedicated to developing and delivering a novel portfolio of new diagnostics, therapeutics, and medical devices from concept to commercialization. From 2013 to 2019, Mr. Daniel served as Chief Financial Officer of Regenerative Medicine Solutions, LLC, which was acquired by H-CYTE in 2019. He currently serves on the Board of Directors of Medovex LLC, a subsidiary of H-CYTE. Mr. Daniel received his BS in Accounting from the University of Cincinnati and his MBA from Xavier University.

In connection with his appointment to the Board, the Board determined that Mr. Daniel is independent under the independence standards of the Nasdaq Stock Market (“Nasdaq”) and is independent under the rules of Nasdaq and the Securities and Exchange Commission (the “SEC”) for purposes of service on the Audit Committee. There are no arrangements or understandings between Mr. Daniel and any other person pursuant to which he was selected as a director, and there are no relationships or transactions in which Mr. Daniel has an interest requiring disclosure under Item 404(a) of Regulation S-K. Mr. Daniel will participate in the Company’s director compensation program, which is described under the heading “Director Compensation” in Item 11., Executive Compensation, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on May 16, 2022.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ALFI, INC. By: /s/ ~~Peter~~Louis ~~Bordes~~Almerini ~~Peter~~Louis ~~Bordes~~Almerini Interim Chief ~~Executive~~Financial Officer

Date: July 828, 2022

Filing Compare · Alfi, Inc.